Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Functional class and physician-perceived severity are similar in treated and untreated patients with pulmonary arterial hypertension: A real-world survey